molecules of the month


mGluR2/3 antagonist prodrug

Ph. II for depression

prodrug of TP0178894 (hydrophilic glutamate analog)

Drug Metab. Dispos., February 8, 2023

Taisho Pharmaceutical Co., Toyko, JP

TP0473292, mGluR2/3 antagonist prodrug, Ph. II for depression, TAISHO PHARMACEUTICAL CO., TOKYO, JP
7 mins read

Drug Hunter Reviewer Commentary. With over two decades of experience in neuroscience drug discovery, Drug Hunter reviewer Jake Schwarz says "mGluR2/3 agonists have been explored for schizophrenia, and agonists/PAMS could be tuned to give antagonist/NAM activity, but depression is a new indication. One of the more interesting depression approaches now is the use of ketamine, an NMDA antagonist. This MoA elicits hallucinations like PCP, but dose is likely critical for the depression indication. It could be that dampening ionotropic or metabotropic glutamate receptors has a beneficial effect in patients with depression." A mechanism with the antidepressant efficacy of ketamine but without the associated adverse effects? Ketamine is a molecule with a long history, starting with its initial development as an…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: